Changeflow GovPing

What do you monitor?

Curated feeds for your role. Pick your area and get exactly the sources you need.

Recent changes

Favicon for changeflow.com

Patent Application for Feeder Cells and Cell Sheet Production

The USPTO has published a new patent application (US20260085290A1) filed by DAI NIPPON PRINTING CO., LTD. The application details a method for producing feeder cells and cell sheets, derived from pluripotent stem cells, intended for maintaining or proliferating difficult-to-culture cells. This is a standard publication of a patent application.

Routine Notice Healthcare
Favicon for changeflow.com

Use of G007-LK for Osteogenic Differentiation and Bone Regeneration

The USPTO has published patent application US20260085289A1, detailing the use of a compound known as G007-LK. The application, filed by the Hospital of Stomatology, Guangzhou Medical University, describes G007-LK's potential to promote osteogenic differentiation of dental stem cells and aid in bone tissue regeneration.

Routine Notice Pharmaceuticals
Favicon for changeflow.com

CRISPR/Cas13a Kit for Rapid ALV-J Detection

The USPTO has published a patent application for a CRISPR/Cas13a kit designed for the rapid detection of avian leukosis virus subgroup J (ALV-J). This application details a method combining CRISPR/Cas13a with recombinase aided amplification for improved sensitivity and specificity in detecting ALV-J.

Routine Notice Pharmaceuticals
Favicon for changeflow.com

Method to enhance CAR-T cell efficacy using NOS inhibitor

The USPTO has published a patent application (US20260083844A1) detailing a method to enhance CAR-T cell efficacy by downregulating nitric oxide synthase (NOS). This application describes a potential therapeutic approach for treating B cell malignancies that are resistant to current CAR-T cell treatments.

Routine Notice Pharmaceuticals
Favicon for changeflow.com

mRNA Vaccine and Immune Modulator Combination Patent Application

The USPTO has published a patent application (US20260083837A1) for a combination comprising mRNA molecules for vaccines or therapeutic proteins, along with immune-modulating mRNA. The application details combinations for improved or reduced immunogenicity to increase efficacy, and relates to host cells, pharmaceutical compositions, vaccines, and kits for medical use.

Routine Guidance Pharmaceuticals
Favicon for changeflow.com

Patent Application: Alpha-Glucosidase Compositions for Pompe Disease Treatment

The USPTO has published a new patent application (US20260083829A1) from Amicus Therapeutics, Inc. The application details compositions comprising high concentrations of acid alpha-glucosidase and active site-specific chaperones for treating Pompe disease. It also covers methods for increasing enzyme stability.

Routine Notice Pharmaceuticals
Favicon for changeflow.com

Patent Application for Treating DNAse1 Deficiency Diseases

The USPTO has published a new patent application (US20260083828A1) detailing compositions and methods for treating diseases associated with DNAse1 and/or DNAse1L3 deficiency. The application was filed on September 11, 2025, by inventors Demetrios Braddock, Paul Stabach, and Ethan Lester.

Routine Notice Pharmaceuticals
Favicon for changeflow.com

Patent Application: Conditioned Media, Cultured Cells Production

The USPTO has published a new patent application, US20260083818A1, detailing a system and method for the production, formulation, and use of conditioned media and cultured cells. The application was filed on May 7, 2025, and describes techniques for culturing various cell types, including animal and plant cells, together.

Routine Notice Pharmaceuticals
Favicon for changeflow.com

Patent Application for Engineered Bacteriophage Transducing Particles Production

The USPTO has published a new patent application (US20260083787A1) from TROBIX BIO LTD. for systems and methods for producing engineered bacteriophage transducing particles. The application details novel approaches for manipulating bacterial populations using these particles and associated regulatory elements.

Routine Notice Pharmaceuticals
Favicon for changeflow.com

Antimicrobial use of Micrococcus porci against Staphylococcus species

The USPTO has published a patent application detailing the selective antimicrobial use of Micrococcus porci against harmful Staphylococcus species. The application describes compositions comprising Micrococcus porci for use in cosmetics, quasi-drugs, external skin preparations, or medicines.

Routine Guidance Pharmaceuticals

Showing 4121–4130 of 33,032 changes

1 411 412 413 414 415 3304

Get alerts when regulations change

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.